Fort Worth, Texas—Although immunotherapy delivers durable responses and survival benefits in patients with previously untreatable tumors, concerns about frequent and often severe immune-related adverse effects (AEs) persist. At the 2019 Hematology/Oncology Pharmacy Association annual meeting, experts compared the advantages and disadvantages of a planned break from immunotherapy to avoid potential AEs in a patient who had achieved a complete response.
Presenters Sara Butler,